Autolus Therapeutics plc

Historical 13F Holders

Symbol
AUTL
CUSIP
05280R100
All holders as of
Q2 2026
Type
Equity
Class
SPON ADS
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 05280R100 since 12/18/2024, newest first.

Filer % of Class Filed
PPF Group a.s. 13D/A Amendment 11
5.6% 8/28/2026
Event 8/27/2026
Armistice Capital, LLC 13G/A Amendment 3
5.6% 8/14/2026
Event 6/30/2026
MAK Capital Fund LP 13G/A Amendment 3
12.6% 5/15/2026
Event 3/31/2026
Armistice Capital, LLC 13G/A Amendment 2
5.9% 5/15/2026
Event 3/31/2026
Armistice Capital, LLC 13G/A Amendment 1
6.6% 2/17/2026
Event 12/31/2025
MAK Capital Fund LP 13G/A Amendment 2
11.3% 2/13/2026
Event 12/31/2025
MAK Capital Fund LP 13G/A Amendment 1
10.1% 12/3/2025
Event 12/1/2025
Armistice Capital, LLC 13G
5.9% 11/14/2025
Event 9/30/2025
Deep Track Capital, LP 13G/A Amendment 4
1.0% 11/14/2025
Event 9/30/2025
Armistice Capital, LLC 13G/A Amendment 3
4.99% 8/14/2025
Event 6/30/2025
MAK Capital Fund LP 13G
5.8% 6/25/2025
Event 6/17/2025
FMR LLC 13G/A Amendment 1
3.8% 5/12/2025
Event 3/31/2025
Syncona Portfolio Ltd 13G/A Amendment 8
10.8% 5/7/2025
Event 3/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 2 16.5 k $32.1 k
2026 Q2 85 132 M $212 M
2026 Q1 88 134 M $184 M
2025 Q4 95 140 M $277 M
2025 Q3 101 146 M $235 M
2025 Q2 98 166 M $379 M
2025 Q1 98 168 M $261 M
2024 Q4 113 168 M $395 M
2024 Q3 106 180 M $653 M
2024 Q2 118 182 M $632 M
2024 Q1 129 177 M $1.13 B
2023 Q4 106 116 M $748 M
2023 Q3 73 111 M $258 M
2023 Q2 73 109 M $260 M
2023 Q1 68 106 M $195 M
2022 Q4 76 108 M $204 M
2022 Q3 68 49.4 M $106 M
2022 Q2 70 50.8 M $144 M
2022 Q1 68 53.0 M $229 M
2021 Q4 82 52.5 M $272 M
2021 Q3 63 25.1 M $164 M
2021 Q2 70 25.4 M $170 M
2021 Q1 64 22.5 M $129 M
2020 Q4 51 14.3 M $128 M
2020 Q3 47 12.4 M $143 M
2020 Q2 52 14.3 M $230 M
2020 Q1 54 16.3 M $98.4 M
2019 Q4 58 13.4 M $177 M
2019 Q3 45 13.4 M $167 M
2019 Q2 47 21.4 M $344 M
2019 Q1 37 18.3 M $577 M
2018 Q4 40 17.0 M $558 M
2018 Q3 41 17.9 M $547 M
2018 Q2 49 9.01 M $241 M